NCI Announces Sites of First Endostatin Phase I Studies

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 5
Volume 8
Issue 5

BETHESDA, Md-The first human trials of the antiangiogenesis drug endostatin will take place at the University of Wisconsin-Madison and the University of Texas M.D. Anderson Cancer Center. The National Cancer Institute (NCI), which will sponsor the phase I trials, said that the studies will begin in late summer or early fall. Protocols for the two studies had not been worked out at the time of the NCI’s announcement.

BETHESDA, Md—The first human trials of the antiangiogenesis drug endostatin will take place at the University of Wisconsin-Madison and the University of Texas M.D. Anderson Cancer Center. The National Cancer Institute (NCI), which will sponsor the phase I trials, said that the studies will begin in late summer or early fall. Protocols for the two studies had not been worked out at the time of the NCI’s announcement.

Each trial will involve 15 to 25 patients with advanced solid tumors that will include lymphoma and lung, breast, colon, and prostate cancers.

Information on the University of Wisconsin-Madison trial is available by calling 1-800-622-8922 or 608-262-5223. The M.D. Anderson Cancer Center information line is 1-800-392-1611 (select option 3)

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content